Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: Dr David Holden

Back to Search
Allen-Philbey K, Stephenson S, Doody G, MacDougall A, Aboulwafaali M, Ammoscato F, Andrews M, Gnanapavan S et al. ( 2024 ) . Effects of cladribine on intrathecal and peripheral B and plasma cells . Clinical & Experimental Immunology
Ammoscato F, Wafa M, Skonieczna J, Bestwick J, Monero R, Andrews M, De Trane S, Holden D et al. ( 2024 ) . Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells . Clinical Immunology vol. 269 ,
Mousele C, Holden D, Gnanapavan S ( 2024 ) . Neurofilaments in neurologic disease . vol. 123 , Elsevier
Ammoscato F, Skonieczna J, Bestwick J, Holden D, Aboulwafa M, Andrews M, Turner B, Marta M et al. ( 2024 ) . Prospective Longitudinal Study of Cladribine Tablets (CLADB Study) Demonstrates Sustained Reduction in Kappa Free Light Chains in Relapsing Multiple Sclerosis (RRMS) at 96 Weeks (P10-6.008) . Neurology vol. 102 , ( 17_supplement_1 )
Dobson R ( 2023 ) . A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with Multiple Sclerosis . Multiple Sclerosis Journal
Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, Giovannoni G, Gnanapavan S et al. ( 2023 ) . Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis . Therapeutic Advances in Neurological Disorders vol. 16 ,
Gold J, Holden D, Parratt J, Yiannikas C, Ahmad R, Sedhom M, Giovannoni G ( 2022 ) . Effect of teriflunomide on Epstein–Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study . Multiple Sclerosis and Related Disorders . vol. 68 ,
Adams A, Tilden W, Bestwick J, Holden D, Bianchi L, Smets I, Giovannoni G, Gnanapavan S ( 2022 ) . The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis . European Journal of Neurology vol. 29 , ( 9 ) 2754 - 2760 .
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2022 ) . Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study . MULTIPLE SCLEROSIS JOURNAL . vol. 28 , 33 - 34 .
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2021 ) . Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study . Multiple Sclerosis and Related Disorders vol. 57 ,
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2021 ) . Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 514 - 515 .
Schmierer K, Gnanapavan S, Giovannoni G, Ammoscato F, Holden D, Carrillo-Loza K, Christmas T, Bianchi L et al. ( 2020 ) . CSF neurofilament light chain testing as an aid to determine treatment strategies in MS . Neurology, Neuroimmunology and Neuroinflammation vol. 7 , ( 6 )
Reyes S, Smets I, Holden D, Carrillo-Loza K, Christmas T, Bianchi L, Ammoscato F, Turner B et al. ( 2020 ) . CSF neurofilament light chain testing as an aid to determine treatment strategies in MS . Neurology Neuroimmunology & Neuroinflammation vol. 7 , ( 6 )
Smets I, Reyes S, Carrillo-Loza K, Mateo-Casas M, Bianchi L, Holden D, Ammoscato F, Turner B et al. ( 2020 ) . CSF Neurofilament Light Chain for guiding individual treatment decisions in multiple sclerosis . EUROPEAN JOURNAL OF NEUROLOGY . vol. 27 , 475 - 476 .
Carrillo-Loza K, Reyes S, Bianchi L, Holden D, Espasandin M, Ammoscato F, Turner B, Schmierer K et al. ( 2019 ) . Real Life Evidence for CSF Neurofilaments Light Chain in Clinical Practice. (P5.2-021) . Neurology vol. 92 , ( 15_supplement )
Reyes S, Carrillo-Loza K, Mateo M, Bianchi L, Holden D, Ammoscato F, Marta M, Turner B et al. ( 2019 ) . Evidence of the utility of CSF neurofilament light chain measurements in people with MS in clinical practice . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 854 - 854 .
Carrillo-Loza K, Reyes S, Bianchi L, Holden D, Espasandin M, Ammoscato F, Turner B, Schmierer K et al. ( 2019 ) . Real life Evidence for CSF Neurofilaments Light Chain in Clinical Practice . NEUROLOGY . vol. 92 ,
Holden DW, Gold J, Hawkes CH, Giovannoni G, Saxton JM, Carter A, Sharrack B ( 2018 ) . Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts . Multiple Sclerosis and Related Disorders vol. 25 , 197 - 199 .
Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al. ( 2018 ) . A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study . Multiple Sclerosis and Related Disorders vol. 24 , 123 - 128 .
Gold J, Marta MC, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al. ( 2016 ) . Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 188 - 189 .
Marta M, MacManus D, Yousry T, Miller D, Altmann DR, Meier UC, Christensen T, Maruszak H et al. ( 2016 ) . Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 188 - 188 .
Gold J, Giovannoni G, Marta MC, Meier U, Miller D, Christensen T, Maruszak H, Holden D et al. ( 2015 ) . Pilot baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study . MULTIPLE SCLEROSIS JOURNAL . vol. 21 , 162 - 162 .
Maghzi AH, Meier U, Holden D, Marta M, Kantor A, Waubant E, Giovannoni G, Goelz S ( 2009 ) . Natural killer cell status in multiple sclerosis and its association with interferon beta-1a treatment . MULTIPLE SCLEROSIS . vol. 15 , S73 - S73 .
Back to Search